ResMed is a medical instruments & supplies business based in the US. ResMed shares (RMD) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $240.00 – an increase of 0.34% over the previous week. ResMed employs 9,980 staff and has a trailing 12-month revenue of around $4.7 billion.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $240.00 |
|---|---|
| 52-week range | $130.88 - $255.18 |
| 50-day moving average | $237.70 |
| 200-day moving average | $205.91 |
| Wall St. target price | $237.93 |
| PE ratio | 34.6821 |
| Dividend yield | $1.92 (0.88%) |
| Earnings per share (TTM) | $6.92 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $240 from 2024-10-18
| 1 week (2024-10-15) | 0.34% |
|---|---|
| 1 month (2024-09-20) | -2.02% |
| 3 months (2024-07-22) | 15.79% |
| 6 months (2024-04-22) | 33.07% |
| 1 year (2023-10-20) | 66.44% |
|---|---|
| 2 years (2022-10-21) | 7.97% |
| 3 years (2021-10-18) | N/A |
| 5 years (2019-10-22) | 92.88% |
Valuing ResMed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of ResMed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
ResMed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, ResMed shares trade at around 35x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
ResMed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.009. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into ResMed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
ResMed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 billion.
The EBITDA is a measure of a ResMed's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $4.7 billion |
|---|---|
| Operating margin TTM | 31.17% |
| Gross profit TTM | $2.4 billion |
| Return on assets TTM | 12.7% |
| Return on equity TTM | 22.7% |
| Profit margin | 21.79% |
| Book value | $33.11 |
| Market Capitalization | $35.2 billion |
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like ResMed.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 29.05
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and ResMed's overall score of 29.05 (as at 12/31/2018) is nothing to write home about – landing it in it in the 50th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like ResMed is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 7.42/100
ResMed's environmental score of 7.42 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 14/100
ResMed's social score of 14 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that ResMed is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 12.64/100
ResMed's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that ResMed is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Controversy score: 1/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. ResMed scored a 1 out of 5 for controversy – the highest score possible, reflecting that ResMed has managed to keep its nose clean.
ResMed Inc was last rated for ESG on: 2019-01-01.
| Total ESG score | 29.05 |
|---|---|
| Total ESG percentile | 50.28 |
| Environmental score | 7.42 |
| Environmental score percentile | 4 |
| Social score | 14 |
| Social score percentile | 4 |
| Governance score | 12.64 |
| Governance score percentile | 4 |
| Level of controversy | 1 |
Dividend payout ratio: 25.49% of net profits
Recently ResMed has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), ResMed shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In ResMed's case, that would currently equate to about $1.92 per share.
While ResMed's payout ratio might seem fairly standard, it's worth remembering that ResMed may be investing much of the rest of its net profits in future growth.
ResMed's most recent dividend payout was on 18 September 2024. The latest dividend was paid out to all shareholders who bought their shares by 14 August 2024 (the "ex-dividend date").
ResMed's shares were split on a 2:1 basis on 30 August 2010 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your ResMed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for ResMed shares which in turn could have impacted ResMed's share price.
Over the last 12 months, ResMed's shares have ranged in value from as little as $130.881 up to $255.1794. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while ResMed's is 0.689. This would suggest that ResMed's shares are less volatile than average (for this exchange).
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; U-Sleep, a compliance monitoring solution that enables home medical equipment (HME) to streamline their sleep programs; connectivity module and propeller solutions; and Propeller portal. It offers out-of-hospital software solution, such as Brightree business management software and service solutions to providers of HME, pharmacy, home infusion, orthotics, and prosthetics services; MatrixCare care management and related ancillary solutions to senior living, skilled nursing, life plan communities, home health, home care, and hospice organizations, as well as related accountable care organizations; HEALTHCAREfirst that offers electronic health record, software, billing and coding services, and analytics for home health and hospice agencies; and MEDIFOX DAN's software solutions. The company markets its products to sleep clinics, home healthcare dealers, and hospitals through a network of distributors and direct sales force.
Fundamental analysis of stocks can help you become a better investor and find the true value of stocks and other assets.
These are the stocks to buy when you don’t have much to spend.
These are the best day trading apps, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
eToro is a robust trading platform with an easy-to-use interface and no commissions on stocks and ETFs.
Titan invest is a members-only automated platform best for hands-off investors looking to build wealth.
A beginner-friendly investing platform with fractional shares and no commissions on stocks and ETFs.
What you need to know about investing in the leading indicator for the overall US stock market.
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Read our beginner’s guide to trading options in the US.